A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease

Model scores of the 29,894 trials active now.

Model score 18% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 19% of the time (731 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-03-06. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: long termextensionassessfailurepatient
  Phrases that lowered it: diseasesvisitsuspectedchildrendisorders
• Phase: 2 (raises risk) · Design
• Sponsor's past termination rate: 9.3% (raises risk) · Sponsor's track record
• Disease area, neurology: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports with a death: 14.2% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 81 (lowers risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Maximum age: 17 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 96.4% (raises risk) · Drug's FDA history
• Sponsor's past trials: 366 (lowers risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease NCT02023866 · started 2014 · scored riskier than 71% of active trials completed
• A Study to Assess TTI-0102 vs Placebo in MELAS Patients NCT06644534 · started 2025 · scored riskier than 15% of active trials completed
• A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease NCT03888716 · started 2019 · scored riskier than 6% of active trials completed
• A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy NCT04378075 · started 2020 · scored riskier than 56% of active trials terminated
• An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead) NCT05267574 · started 2022 · scored riskier than 98% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.